Navigation Links
Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Date:11/29/2007

CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that Dr. Matt Coffey, Chief Scientific Officer of Oncolytics, is scheduled to deliver a presentation on Wednesday, December 5, 2007 entitled "Large Scale Production Process for the Oncolytic Agent REOLYSIN(R) (Human Reovirus)" at the Informa Life Sciences' 3rd Annual Vaccine Production Conference in Cologne, Germany. The conference runs from December 4-5, 2007.
For more information about the conference, please visit

http://www.informa-ls.com/vaccines.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the manufacturing process presented at this conference, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's abilit
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Kerastem Technologies announce that the Company has received ... For Biologics Evaluation and Research (CBER) Office of Cellular, ... investigating the safety and feasibility of the Company,s technology ... baldness (androgenic alopecia). The phase II study, ... in Europe and ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
(Date:7/27/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... on Thursday, July 30, 2015, after the close of ... by a conference call with the investment community at ... will be Robert A. Bradway , chairman and ... management team. Live audio of the conference ...
(Date:7/27/2015)... London, UK (PRWEB) , ... July 27, 2015 , ... ... stable growth over the past few years in the EU. For instance, it surpassed ... approximately the EUR 92 million mark in 2010. Germany is a major producer, while ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... Mich., Sept. 30 GeneGo Inc., a leading,provider ... announced,today that they were awarded with a Phase ... for the development of a platform for understanding,the ... GeneGo,will collaborate with FDA investigator, Jim Kaput Director ...
... balanced a laptop computer on your lap lately, you ... speeds are creating more and more heat, which has ... lap. , Two researchers at the University of Virginia,s ... the scientific groundwork that will solve the problem using ...
... Tam Whistleblower Attorney Brian P. Kenney, Esq. Filed ... Additional Complaints Were Filed; $375 Million Civil ... Corporate Criminal Fine Today, PHILADELPHIA, Sept. 29 ... a grand scale,for years by off-label marketing its first ...
Cached Biology Technology:GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA 2Engineers aim to solve 'burning' computer problem 2$425 Million Cephalon Civil Settlement and Criminal Fine; In America's Largest 2$425 Million Cephalon Civil Settlement and Criminal Fine; In America's Largest 3
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... 9, 2012 Human cells are thought to produce thousands ... determine which genes are turned on or off at a ... function, but they can also contribute to human diseasesome are ... survival. But to better understand how miRNAs influence health and ...
... Women,s Hospital (BWH), the ingredient that gives hot sauce ... of weight loss. Ali Tavakkoli, MD, BWH ... study investigating whether two surgeries called vagal de-afferentationwhich uses ... sensationand vagatomy can achieve weight loss and reduce the ...
... from Queen Mary, University of London have found a ... published in the journal Cellular and Molecular Life ... important for regulating inflammation. The findings could lead to ... arthritis*. Dr Martin Knight who led the ...
Cached Biology News:It's a trap! New laboratory technique captures microRNA targets 2Hot sauce ingredient reduces 'beer belly' fat as a weight-loss surgery alternative 2
Complete cell culture media with cytokines...
... multiple tissue panels are designed for ... genes or proteins of interest in ... on positively charged glass slides. Total ... the identical format, and cDNA from ...
8 different frozen tissues are mounted on positively charged glass slides...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Biology Products: